Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
AbbVie Signs $3.9 Billion Oncology Deal with Genmab
03:26pm, Wednesday, 10'th Jun 2020
The pace of development for a handful of next-generation cancer therapies is about to get a huge boost. AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) signed a collaboration deal on Wednesday involvin
AbbVie Can Withstand Humira’s Decline With New Drugs
02:29pm, Wednesday, 10'th Jun 2020
Evercore ISI analyst Josh Schimmer resumed coverage of AbbVie stock with an Outperform rating and $111 price target. Humira’s erosion will be offset by sales growth in AbbVie’s next-generation tre
AbbVie and Genmab Ink $4 Billion Cancer-Treatment Pact
02:18pm, Wednesday, 10'th Jun 2020
AbbVie and Genmab announce a $4 billion pact to develop and commercialize a series of Genmab's early-stage cancer treatments.
Abbvie partners with Genmab in $750 million cancer therapy deal
11:38am, Wednesday, 10'th Jun 2020The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset
11:30am, Wednesday, 10'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) * Dr.Reddy's Laboratories Ltd (NYSE: RDY) * Imara Inc
Genmab's stock surges after drug development deal with AbbView valued at up to nearly $4 billion
10:12am, Wednesday, 10'th Jun 2020
Shares of Genmab A/S rose 4.5% in premarket trading Wednesday, after the Denmark-based biotechnology company announced a collaboration agreement with AbbVie Inc. valued at up to nearly $4 billion to
AbbVie and Genmab Announce Broad Oncology Collaboration
10:00am, Wednesday, 10'th Jun 2020
AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that AbbVie and Genmab have signed a broad collaboration agreement to jointly develop and commercialize three of Genmab's early-stage
Top Biotech Stocks for Q3 2020
06:09pm, Tuesday, 09'th Jun 2020
The biotechnology industry includes companies that develop drugs and diagnostic compounds for the treatment of diseases and medical conditions. This means that investors may wait for years before kno
Biotech ETFs Are Soaring. These Four Are Still Worth Considering.
12:00pm, Monday, 01'st Jun 2020
Investors have been bullish on biotech, in the hope that companies will soon come up with a treatment, cure, or vaccine for Covid-19. But there’s more to biotech than the coronavirus, and even thoug
Genmab's Shares March Higher, Can It Continue?
10:35am, Wednesday, 20'th May 2020
As of late, it has definitely been a great time to be an investor in Genmab.
How Does Genmab's (CPH:GMAB) P/E Compare To Its Industry, After Its Big Share Price Gain?
04:48am, Wednesday, 13'th May 2020
Genmab (CPH:GMAB) shareholders are no doubt pleased to see that the share price has had a great month, posting a 34...
Genmab A/S (GMAB) Q1 2020 Earnings Call Transcript
02:00pm, Thursday, 07'th May 2020
Ladies and gentlemen, thank you for standing by, and welcome to Genmab's First Quarter Report 2020 Conference Call. Genmab is not under an obligation to update statements regarding the future nor to
Genmab A/S to Host Earnings Call
08:00pm, Wednesday, 06'th May 2020
NEW YORK, NY / ACCESSWIRE / May 6, 2020 / Genmab A/S (NASDAQ:GMAB) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 6, 2020 at 6:00 PM Eastern Time
H.C. Wainwright Believes Genmab (NASDAQ: GMAB) Still Has Room to Grow
11:29am, Friday, 01'st May 2020
H.C. Wainwright analyst
Ram Selvaraju
reiterated a
Buy
rating on Genmab (
GMAB
–
Research Report
) today and set a price target of
$28.00
. The company’s shares closed last Thursday at $24.33, clo
Genmab (GMAB) Received its Third Buy in a Row
11:14am, Monday, 27'th Apr 2020
After RBC Capital and Morgan Stanley gave Genmab (NASDAQ: GMAB) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright.
